Lumida
/LENZ
⌘K
LENZ Therapeutics Inc

LENZ Therapeutics Inc

LENZ
$5.18USD↑+6.15%+0.30 today

MARKET CAP

162.4M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$5 – $5

52W RANGE

$5
$50

AI Summary

Stalk
TrimMedium

LENZ is in a Stage 4 decline with persistent lower highs and lower lows under down-sloping EMAs, confirming bearish structure across both medium and long terms. Short-term execution timing is neutral as price tightly tracks below declining EMAs amid extreme oversold readings, offering no clear entry. With a speculative strategy requiring high selectivity, execution is deferred and best considered on any rally into EMA resistance.

  • ↑Q1 revenue $1.9M from ~25K VIZ prescriptions, 19% QoQ growth
  • ↑Telehealth prescribing option launched for direct home delivery access
  • ↓Q1 net loss $41.5M exceeded revenue; SG&A set to total $80–100M
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

LENZ Therapeutics, Inc. (NASDAQ: LENZ) is a prominent player focusing on innovative ophthalmic therapies, particularly targeting presbyopia with its lead product, VIZ. Having received FDA approval, the company seeks to establish itself within a substantial market estimated to affect around 128 million Americans. LENZ aims to meet the growing demand for effective treatments in an underserved sector while leveraging modern marketing strategies to enhance patient and physician engagement.

Bull says

  • ↑Q1 revenue $1.9M from ~25K VIZ prescriptions, 19% QoQ growth
  • ↑Telehealth prescribing option launched for direct home delivery access
  • ↑VIZ’s pupil-selective formula shows zero retinal detachments, strong safety
  • ↑DTC campaigns with Sarah Jessica Parker drove 10× website traffic
  • ↑$258.4M cash reserves support operations and marketing initiatives
  • ↑Positive liquidity and book-to-price ~1.07 suggest potential undervaluation

Bear says

  • ↓Q1 net loss $41.5M exceeded revenue; SG&A set to total $80–100M
  • ↓Earnings yield negative; high leverage risk stresses profitability
  • ↓Prescription uptake more gradual than guided, adoption below expectations
  • ↓Rising competition from TenPoints and Uvesi may dilute market share
  • ↓International expansion tied to regulatory approvals through 2027
  • ↓Analysts trimming estimates, signaling skepticism on forecasts

Investment themes with LENZ

Pharmaceuticals↓ -1.67%

Drug development driving global healthcare solutions

JNJ · LLY · RPRX

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-12-2026neutral

Transcript signals

Bull points

  • we are encouraged by the performance of VIZ in the hands of patients and ECPs as we build the presbyopia market.
  • The early signs of broad ECP uptake are there, as evidenced by over 10,000 prescribers in the first two quarters of launch, a figure higher than any recent launch in ophthalmology at this stage.
  • Our first quarter results were highlighted by the approximately 25,000 data-filled prescriptions of this, which was a 19% increase compared to Q4, resulting in approximately $1.7 million in net product revenues.

Bear points

  • $45 million in Q1, 2026, or approximately $40.7 million net of non-cash stock-based compensation. This was a 13% quarter-over-quarter increase from Q4, and it was driven by our planned DTC launch investment.
  • we anticipate that our Q1 2026 OpEx, SG&A, and the resulting cash burn is higher than our go-forward quarterly loan rate over the balance of 2026.
  • our net loss per share, both basic and diluted, was $1.32 per share in the first quarter of 2026 on a net loss of $41.5 million.
Read full transcript analysis ›